Understanding and treating muscle wasting in pancreatic cancer patients
Training and Research on Mechanisms of Pancreatic Cancer Associated Muscle Wasting and Related Therapies
This study is looking at why some people with pancreatic cancer lose muscle and is testing new ways to help prevent that muscle loss, using a mouse model to better understand the problem and find effective treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10886564 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind skeletal muscle wasting (SMW) in patients with pancreatic ductal adenocarcinoma (PDAC) and explores potential therapies to combat this condition. By developing a mouse model that mimics human disease, researchers are able to study the biological processes involved in SMW and test new treatment options. The study focuses on identifying inflammatory factors and other biological markers that contribute to muscle loss, with the aim of improving patient outcomes during cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are experiencing or at risk of skeletal muscle wasting.
Not a fit: Patients with other types of cancer or those not experiencing muscle wasting may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective therapies that prevent or reduce muscle wasting in pancreatic cancer patients, enhancing their ability to tolerate treatments and improving survival rates.
How similar studies have performed: While the specific approach of this research is novel, there have been other studies indicating that addressing muscle wasting in cancer patients can improve treatment outcomes.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Cole, Calvin Lloyd — University of Rochester
- Study coordinator: Cole, Calvin Lloyd
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.